# Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece

> **NCT02821247** · — · COMPLETED · sponsor: **Bayer** · enrollment: 119 (actual)

## Conditions studied

- Choroidal Neovascularization
- Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT02821247
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-12-13
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821247, "Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02821247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*